Pratiksha Gulati
Overview
Explore the profile of Pratiksha Gulati including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
167
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cowan K, Kunz U, Blattmann P, Gulati P, Hughes R, Andersen L, et al.
Bioanalysis
. 2024 Aug;
16(16):835-842.
PMID: 39101487
The European Bioanalysis Forum, alongside key industry stakeholders, has been driving the discussions around the implementation of context-of use for biomarker assays to ensure that these assays are validated appropriately...
2.
Klughammer B, Piali L, Nica A, Nagel S, Bailey L, Jochum C, et al.
Clin Transl Med
. 2023 Nov;
13(11):e1471.
PMID: 37962000
Background: The NLRP3 inflammasome drives release of pro-inflammatory cytokines including interleukin (IL)-1β and IL-18 and is a potential target for ulcerative colitis (UC). Selnoflast (RO7486967) is an orally active, potent,...
3.
Natoli M, Hatje K, Gulati P, Junker F, Herzig P, Jiang Z, et al.
J Immunother Cancer
. 2022 Nov;
10(11).
PMID: 36319064
Background: Next-generation cancer immunotherapies are designed to broaden the therapeutic repertoire by targeting new immune checkpoints including lymphocyte-activation gene 3 (LAG-3) and T cell immunoglobulin and mucin-domain containing-3 (TIM-3). Yet,...
4.
Junker F, Gulati P, Wessels U, Seeber S, Stubenrauch K, Codarri-Deak L, et al.
Cytometry A
. 2021 Mar;
99(8):832-843.
PMID: 33704890
Receptor occupancy (RO) assessment by flow cytometry is an important pharmacodynamic (PD) biomarker in the clinical development of large molecules such as monoclonal therapeutic antibodies (mAbs). The total-drug-bound RO assay...
5.
Gulati P, Ruhl J, Kannan A, Pircher M, Schuberth P, Nytko K, et al.
Clin Cancer Res
. 2018 May;
24(16):3981-3993.
PMID: 29748183
Combination therapy of adoptively transferred redirected T cells and checkpoint inhibitors aims for higher response rates in tumors poorly responsive to immunotherapy like malignant pleural mesothelioma (MPM). Only most recently...
6.
Schuberth P, Hagedorn C, Jensen S, Gulati P, van den Broek M, Mischo A, et al.
J Transl Med
. 2013 Aug;
11:187.
PMID: 23937772
Introduction: Malignant pleural mesothelioma (MPM) is an incurable malignant disease, which results from chronic exposition to asbestos in at least 70% of the cases. Fibroblast activation protein (FAP) is predominantly...